The Modulation Study

Currently Recruiting

6 Aug 2026

Up to $9,190

Melbourne, Australia

This study drug is being developed because most current treatments for conditions like Alzheimer’s and Parkinson’s only help with symptoms, rather than fixing what’s actually going wrong in the brain as we age. One of the key problems is that brain cells gradually lose their ability to clean out waste, such as damaged parts and harmful proteins, which then build up and cause further damage. 

The study drug is designed to switch on the brain’s natural “clean‑up system,” helping cells remove this waste more effectively. By restoring this basic housekeeping process inside brain cells, the drug aims to slow or change the disease process itself, not just mask symptoms. Because this same problem is shared across several neurodegenerative diseases, the approach could potentially help more than one condition. 

This first‑in‑human Phase 1 study is an early but essential step to make sure the drug is safe, well tolerated, and behaves as expected in the body before it is tested in people with these diseases. 

Apply now Speak with us 1300 318 674

Join our clinical trial

This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. It is not known whether the study drug may cause unexpected, serious, or life-threatening side effects. While these are considered unlikely, you will be carefully monitored throughout the study and provided with prompt treatment if any such effects occur. 

What to expect

  • Participation in a monitored clinical environment 
  • Study visits scheduled  
  • Support from a professional medical team 
  • Reimbursement for your time and commitment 

Study schedule

 

Intake 1 In-clinic stay:

6 August 2026 – 24 August 2026

 Follow-up visits:

28 August 2026
Intake 2 In-clinic stay:

9 August 2026 – 27 August 2026

 Follow-up visits:

31 August 2026

Study dates are subject to change. Our team will confirm details with you during the screening process.

Trial details

Study duration

  • 18-night stay
  • 1 follow-up visit
  • 1 follow-up phone call

Study medication

Administered via oral tablet

Additional eligibility

  • Weight above 50kg for males 
  • Weight above 45kg for females 
  • BMI between 18 and 32 kg/m²  
  • Non-smokers , or smoking less than 5 cigarettes per week 
  • Not pregnant or breastfeeding   
  • Willing to follow contraception guidelines (If applicable)  

Ethics

An independent ethics committee has approved this clinical trial.

Are you a match?

Age

18 - 55 years old

Remuneration

Up to $9,190 *with screening reimbursement.
Full details outlined in consent form.

Gender

Male, Female or Female (Post-menopausal)

BMI

BMI 18 - 32 kg/m2

Commitment

18 nights, 1 clinic visit

Medical condition

Not taking any medications

Register your interest

This form takes around 3–5 minutes to complete. Your information will remain confidential and is used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1800 243 733


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg






















Step 2 of 3
Medical History

We regularly have studies that allow participants who are (social) smokers.

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Study Preferences

While longer studies generally have a higher reimbursement, there are also studies with multiple short stays that have high reimbursements.
Referral Information


Consent to Information Use and Future Contact